Veradermics, Incorporated (MANE) Key Metrics
MANE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.55B
- Enterprise value
- $4.12B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 6.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
MANE key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMANE returns How much profit the business earns on the capital it uses.
MANE per-share figures Results divided by the shares outstanding at year-end.
MANE financial health Debt, liquidity and how easily interest is covered.
MANE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MANE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MANE key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Per share | |||
| Revenue per share | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.00 | −$0.13 | −$0.08 |
| Operating cash flow per share | −$2.04 | −$0.12 | −$0.07 |
| Free cash flow per share | −$2.04 | −$0.12 | −$0.07 |
| Cash per share | $4.04 | $0.26 | $0.08 |
| Book value per share | −$3.45 | $0.27 | $0.07 |
| Tangible book value per share | −$3.45 | $0.27 | $0.07 |
| Capex per share | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.00 | — | $0.00 |
| Shares outstanding | 35.1M | 201.3M | 201.3M |
| Change in shares outstanding | −82.6% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | — | −76.5% | −112.8% |
| Return on assets (ROA) | −66.0% | −68.1% | −89.3% |
| Return on tangible assets | −45.9% | −44.6% | −89.3% |
| Financial health | |||
| Total debt | $4,000 | — | $786,000 |
| Cash & short-term investments | $141.9M | $53.1M | $16.3M |
| Net debt | −$141.9M | −$53.1M | −$15.5M |
| Debt / equity | — | — | 0.05 |
| Debt / assets | 0.00 | — | 0.04 |
| Current ratio | 16.66 | 11.77 | 5.75 |
| Quick ratio | 16.66 | 11.77 | 5.75 |
| Interest coverage | — | -45.8 | -481.2 |
| Working capital | $143.3M | $50.8M | $14.5M |
| Invested capital | −$262.9M | $1.6M | −$892,000 |
| Tangible asset value | −$121.0M | $54.7M | $14.6M |
| Net current asset value | −$121.1M | $50.8M | $13.7M |
| Graham net-net per share | −$3.73 | $0.25 | $0.06 |
| Efficiency | |||
| Receivables turnover | 0.00 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.3M | $1.4M | — |
| Average payables | $2.2M | $2.0M | $1.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from MANE's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MANE valuation and financial ratios
It ended the year with $0.0 million of debt and $141.9 million in cash and short-term investments, a net cash position of $141.9 million.
See the MANE income statement, the MANE chart for price history, or the MANE stock overview for the latest quote and news.
MANE key metrics FAQ
How much debt does Veradermics have?
Veradermics had total debt of $0.0 million at the end of fiscal 2025 and more cash than debt.
What is Veradermics's current ratio?
Veradermics's current ratio was 16.66 at the end of fiscal 2025: current assets were 16.66 times current liabilities.